Methods and compositions for detecting risk of cancer relapse

A composition, cancer technology, applied in the directions of microorganism-based methods, drug combinations, biochemical devices and methods, which can solve the problem that the role of colonization against specific pathogen resistance is not fully understood, etc.

Pending Publication Date: 2022-01-28
MEMORIAL SLOAN KETTERING CANCER CENT
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Bacteria antagonize enteric pathogens directly and indirectly by modulating and inducing host immune responses through contact-dependent and soluble factor-mediated inhibition, but the contribution of individual bacteria to colonization resistance against specific pathogens is not well understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for detecting risk of cancer relapse
  • Methods and compositions for detecting risk of cancer relapse
  • Methods and compositions for detecting risk of cancer relapse

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0210] Example 1: Certain gut microbes linked to risk of cancer recurrence in cancer patients

[0211] method

[0212]In the present example, a biomarker discovery approach was applied and a retrospective observational analysis of 160 adults who received unmodified (T cell added) allografts was performed. Patients prospectively participate in a fecal biological sample collection protocol. For this analysis, we selected patients who had provided at least one sample during the first 3-week period after allo-HSCT. The major diseases in this cohort were AML (37%), non-Hodgkin's lymphoma (33%), ALL (8%), MDS (7%), CLL (6%), Hodgkin's lymphoma (6%) %), CML (2%), and myeloproliferative neoplasms (2%). The mean age of the patients was 52 years (range 21-75). It was adjusted with ablative (17%), reduced intensity (64%) and nonmyeloablative (19%) regimens. They received transplants from cord blood (46%), unrelated adults (33%), or related adults (22%). Of the adult grafts, 92%...

example 2

[0225] Example 2: Enteroaminococcus abundance in the gut microbiota of cancer patients is associated with reduced risk of cancer recurrence

[0226] method

[0227] 2,391 weekly stool samples from 613 adult cancer patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) were collected over three weeks and analyzed as described in Example 1 to determine the levels of bacteria present in the samples. In this example, the V4-V5 region of the bacterial 16S rRNA gene was sequenced. Samples were collected from days 0-21 after allo-HSCT. Exclusion of 147 patients from the study allowed for analysis of a final cohort of 466 patients. The characteristics of the cohort of 466 patients are provided in Table 2. The cohort exhibited a 26% cancer recurrence rate within 36 months after allo-HSCT ( Figure 9 ).

[0228] Table 2: Cancer and Treatment in 466 Adult Patient Populations

[0229]

[0230] result

[0231] Data from these experiments further ...

example 3

[0234] Example 3: Abundance of bacterial colonies including Eubacterium militaris in gut microbiota of cancer patients is associated with reduced disease progression Linked to risk of cancer recurrence

[0235] method

[0236]Stool samples from 541 adult cancer patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) were collected and sequenced using 16S ribosomal sequencing. Patients prospectively participate in a fecal biological sample collection protocol. Each patient had a sequenced sample taken within the first 21 days after allo-HSCT. The characteristics of the cohort of 541 patients are described in Table 3. During the two-year analysis period, there were 138 relapse / POD events (25.5% incidence).

[0237] Includes patients who have previously undergone autologous stem cell transplantation. Patients with non-malignant indications and those with rare diseases not classifiable by the refined disease risk index (Armand et al. Blood 2014...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to methods and compositions for reducing the risk of cancer relapse in a subject who has received cancer treatment. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Streptococcus anginosus, Parvimonas micra, Acidaminococcus intestini, Eubacterium limosum, Clostridium glycyrrhizinilyticum, Desulfosporosinus lacus, Eubacterium biforme, Anaerofustis stercorihominis, Pseudoramibacter alactolyticus, Peptococcus niger, Armatimonas rosea, Saccharofermentans acetigenes, Finegoldia magna, Levyella massiliensis, Gallicola barnesae, Murdochiella asaccharolytica, and Eubacterium brachy are associated with a reduced risk of cancer relapse.

Description

[0001] This application is a divisional application of a patent application with an application date of September 2, 2016, an application number of 201680063917.3, and an invention title of "Method and Composition for Detecting Cancer Recurrence Risk". [0002] Cross References to Related Applications [0003] This application claims U.S. Provisional Application No. 62 / 214,604 filed on September 4, 2015, U.S. Provisional Application No. 62 / 265,327 filed on December 9, 2015, and U.S. Provisional Application No. Priority No. 62 / 298,258, the contents of each of which are claimed and are each incorporated herein in their entirety. technical field [0004] The present invention relates to compositions and methods for diagnosing an individual at higher or lower risk of cancer recurrence, and compositions and methods for treating said individual. Background technique [0005] The mammalian gastrointestinal tract is densely colonized by hundreds of microbial species that coexist w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K35/744A61K35/741A61K35/74A61K35/28A61P35/00C12Q1/6886C12Q1/689C12Q1/04
CPCA61K45/06A61K35/744A61K35/741A61K35/74A61K35/28A61K9/0043A61K9/0031A61K9/0053A61P35/00C12Q1/6886C12Q1/689C12Q2600/158A61K2300/00C12N1/20A23L33/135A61K38/164C12R2001/01C12N1/205A23V2002/00
Inventor M·万登布林克R·耶齐J·U·佩莱德
Owner MEMORIAL SLOAN KETTERING CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap